Opebacan
Alternative Names: BPI 21; Neuprex; rBPI21; Recombinant bactericidal permeability increasing protein 21Latest Information Update: 17 Jul 2026
At a glance
- Originator New York University
- Developer XOMA
- Class Antibacterials; Recombinant proteins
- Mechanism of Action Angiogenesis inhibitors; Cell membrane permeability enhancers
-
Orphan Drug Status
Yes - Meningococcal infections
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Meningococcal infections; Postoperative infections; Radiation injuries; Wound infections
- Discontinued Graft-versus-host disease; Post-traumatic infections